[
  {
    "ts": null,
    "headline": "Earnings live: Keurig Dr. Pepper stock pops, Waste Management and Whirlpool slip with Big Tech results on deck",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=77ec2bb4cd8375cdc88c8e8c31c6faa741da4e3fc27cbf3b7ec5128ffc89b1fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761598283,
      "headline": "Earnings live: Keurig Dr. Pepper stock pops, Waste Management and Whirlpool slip with Big Tech results on deck",
      "id": 137235229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=77ec2bb4cd8375cdc88c8e8c31c6faa741da4e3fc27cbf3b7ec5128ffc89b1fd"
    }
  },
  {
    "ts": null,
    "headline": "Polen Global Growth's Q3 2025 Portfolio: A Mix Of Durable Earnings Growth And Conviction",
    "summary": "Polen Capital reviews Q3 2025 portfolio performance, AI-led positioning, and new holdings. Explore their long-term growth strategy and conviction-led decisions.",
    "url": "https://finnhub.io/api/news?id=503b208780459242c6de944553267988ba00739733a37f55880db9e343d347d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761597000,
      "headline": "Polen Global Growth's Q3 2025 Portfolio: A Mix Of Durable Earnings Growth And Conviction",
      "id": 137232713,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160051571/image_1160051571.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Polen Capital reviews Q3 2025 portfolio performance, AI-led positioning, and new holdings. Explore their long-term growth strategy and conviction-led decisions.",
      "url": "https://finnhub.io/api/news?id=503b208780459242c6de944553267988ba00739733a37f55880db9e343d347d6"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC).",
    "url": "https://finnhub.io/api/news?id=fe46e914cb1fff7af220bb648355ef53ee02af5473171fef43fa99db9ecd61b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761595500,
      "headline": "Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis",
      "id": 137235359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC).",
      "url": "https://finnhub.io/api/news?id=fe46e914cb1fff7af220bb648355ef53ee02af5473171fef43fa99db9ecd61b6"
    }
  },
  {
    "ts": null,
    "headline": "Lilly declares fourth-quarter 2025 dividend",
    "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock.",
    "url": "https://finnhub.io/api/news?id=53267a2804d2895f62acc30e85777a9178601893a3798d0be578818e1fd8092a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761588000,
      "headline": "Lilly declares fourth-quarter 2025 dividend",
      "id": 137230914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock.",
      "url": "https://finnhub.io/api/news?id=53267a2804d2895f62acc30e85777a9178601893a3798d0be578818e1fd8092a"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced a new partnership with NBA Hall of Famer and cultural icon Shaquille O'Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA). The initiative aims to educate the public about the symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity.",
    "url": "https://finnhub.io/api/news?id=7c45a7218e6146585f97d3d0c50f2ec33978f03521a90a591eb9af2e9f7ebd0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761584400,
      "headline": "Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea",
      "id": 137230915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced a new partnership with NBA Hall of Famer and cultural icon Shaquille O'Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA). The initiative aims to educate the public about the symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity.",
      "url": "https://finnhub.io/api/news?id=7c45a7218e6146585f97d3d0c50f2ec33978f03521a90a591eb9af2e9f7ebd0c"
    }
  },
  {
    "ts": null,
    "headline": "What Is 1 of the Best Pharmaceutical Stocks to Buy Now?",
    "summary": "This pharma giant is entering the rapidly expanding market for weight loss drugs.",
    "url": "https://finnhub.io/api/news?id=ca78798d5c35458977cd4299c0e5768b36fad842a89b3c5c6895bce2a89bf150",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761582082,
      "headline": "What Is 1 of the Best Pharmaceutical Stocks to Buy Now?",
      "id": 137230311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This pharma giant is entering the rapidly expanding market for weight loss drugs.",
      "url": "https://finnhub.io/api/news?id=ca78798d5c35458977cd4299c0e5768b36fad842a89b3c5c6895bce2a89bf150"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly: “It’s Become Luckless”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the company needs to find a new use for its GLP-1 drug, as he stated: “How about Eli Lilly? Now, I hate to say it, but it’s become luckless. If the company doesn’t […]",
    "url": "https://finnhub.io/api/news?id=39153cbaa131a9c9f283c793143063cebe984355f456f699c6609b00d99c4316",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761580477,
      "headline": "Jim Cramer on Eli Lilly: “It’s Become Luckless”",
      "id": 137230917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the company needs to find a new use for its GLP-1 drug, as he stated: “How about Eli Lilly? Now, I hate to say it, but it’s become luckless. If the company doesn’t […]",
      "url": "https://finnhub.io/api/news?id=39153cbaa131a9c9f283c793143063cebe984355f456f699c6609b00d99c4316"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
    "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",
    "url": "https://finnhub.io/api/news?id=057f3ad06e55bc44adb41ef797b5ff64f324132986bd4b6e788158e89c3b0d3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761577500,
      "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
      "id": 137230292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",
      "url": "https://finnhub.io/api/news?id=057f3ad06e55bc44adb41ef797b5ff64f324132986bd4b6e788158e89c3b0d3c"
    }
  },
  {
    "ts": null,
    "headline": "Down 15%, Should You Buy the Dip on Eli Lilly?",
    "summary": "Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy.",
    "url": "https://finnhub.io/api/news?id=e9d9e20a59e8d54a67e0a1ac9d51ebc8fef2782eee31b0dda5534c081b1f3de7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761577200,
      "headline": "Down 15%, Should You Buy the Dip on Eli Lilly?",
      "id": 137228517,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy.",
      "url": "https://finnhub.io/api/news?id=e9d9e20a59e8d54a67e0a1ac9d51ebc8fef2782eee31b0dda5534c081b1f3de7"
    }
  },
  {
    "ts": null,
    "headline": "Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings",
    "summary": "Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.",
    "url": "https://finnhub.io/api/news?id=74c59d0a3df0f2b5d14a612644e312a58be997943bd0398e8786f486b105a250",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761573120,
      "headline": "Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings",
      "id": 137228518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.",
      "url": "https://finnhub.io/api/news?id=74c59d0a3df0f2b5d14a612644e312a58be997943bd0398e8786f486b105a250"
    }
  },
  {
    "ts": null,
    "headline": "Baron Health Care Fund Q3 2025 Top Contributors And Detractors",
    "summary": "Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Read more here.",
    "url": "https://finnhub.io/api/news?id=a14837d187021f8fee8db86afc8e31cb5f3c8ed677257bf29ae1ec7d698e180c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761571620,
      "headline": "Baron Health Care Fund Q3 2025 Top Contributors And Detractors",
      "id": 137230524,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195580261/image_2195580261.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Read more here.",
      "url": "https://finnhub.io/api/news?id=a14837d187021f8fee8db86afc8e31cb5f3c8ed677257bf29ae1ec7d698e180c"
    }
  },
  {
    "ts": null,
    "headline": "Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
    "url": "https://finnhub.io/api/news?id=4852888f4b4ce7e9c4df020e727cd5df1a4c20c2dc4111101a3a523da7aaf6b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761570902,
      "headline": "Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics",
      "id": 137228519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
      "url": "https://finnhub.io/api/news?id=4852888f4b4ce7e9c4df020e727cd5df1a4c20c2dc4111101a3a523da7aaf6b9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly buys Adverum in eye disease gene therapy punt",
    "summary": "For Adverum, the potential buyout from Eli Lilly provides financial respite.",
    "url": "https://finnhub.io/api/news?id=4f1fcaff77a8dcb4a6b94b40151f42d62ae6a6f5270069e91959ab409f69087c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761567382,
      "headline": "Eli Lilly buys Adverum in eye disease gene therapy punt",
      "id": 137228520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "For Adverum, the potential buyout from Eli Lilly provides financial respite.",
      "url": "https://finnhub.io/api/news?id=4f1fcaff77a8dcb4a6b94b40151f42d62ae6a6f5270069e91959ab409f69087c"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Keurig Dr. Pepper stock pops as investors await Big Tech earnings from Apple, Google, and more",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=d985e4a83ea21163bb9aaabf6a7d82771e58096fa9818cb3f140429c6914a413",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761566506,
      "headline": "Earnings live: Keurig Dr. Pepper stock pops as investors await Big Tech earnings from Apple, Google, and more",
      "id": 137228420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=d985e4a83ea21163bb9aaabf6a7d82771e58096fa9818cb3f140429c6914a413"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Eli Lilly Stock Before Oct. 30?",
    "summary": "Long-term investors don't need to rush to buy Eli Lilly stock.",
    "url": "https://finnhub.io/api/news?id=7692cc2eb21df545dffa48e6b304c91336f90d490ddfff3bb5711f9d2b488310",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761564660,
      "headline": "Should You Buy Eli Lilly Stock Before Oct. 30?",
      "id": 137228522,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Long-term investors don't need to rush to buy Eli Lilly stock.",
      "url": "https://finnhub.io/api/news?id=7692cc2eb21df545dffa48e6b304c91336f90d490ddfff3bb5711f9d2b488310"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis",
    "summary": "New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis (UC) and bowel urgency experienced early improvements in bowel urgency severity, frequency and stool deferral time by Week 12. These outcomes continued to improve through 28 weeks. The Phase 3b single-arm, open-label LUCENT-URGE study was specifically designed to assess bowel urgency and is the first in inflammatory bowel disease to include the novel endpoints of bo",
    "url": "https://finnhub.io/api/news?id=0c9df9ba2704dc892a8d884a09fa64d757e3b451197c373be911392b7a50d86f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761561900,
      "headline": "Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis",
      "id": 137228523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis (UC) and bowel urgency experienced early improvements in bowel urgency severity, frequency and stool deferral time by Week 12. These outcomes continued to improve through 28 weeks. The Phase 3b single-arm, open-label LUCENT-URGE study was specifically designed to assess bowel urgency and is the first in inflammatory bowel disease to include the novel endpoints of bo",
      "url": "https://finnhub.io/api/news?id=0c9df9ba2704dc892a8d884a09fa64d757e3b451197c373be911392b7a50d86f"
    }
  },
  {
    "ts": null,
    "headline": "Goldman’s New Fund Designed for PE Returns, Sans the PE",
    "summary": "The Goldman Sachs MSCI World Private Equity Return Tracker ETF does its best to replicate PE performance with publicly traded stocks.",
    "url": "https://finnhub.io/api/news?id=7cb1a495d04ccb95f3059d06a95cf5ee18cc4e84565bc3af07559c229b35f9ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761559800,
      "headline": "Goldman’s New Fund Designed for PE Returns, Sans the PE",
      "id": 137230919,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Goldman Sachs MSCI World Private Equity Return Tracker ETF does its best to replicate PE performance with publicly traded stocks.",
      "url": "https://finnhub.io/api/news?id=7cb1a495d04ccb95f3059d06a95cf5ee18cc4e84565bc3af07559c229b35f9ed"
    }
  },
  {
    "ts": null,
    "headline": "Novartis to Acquire Avidity Biosciences for $72 per Share",
    "summary": "Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th",
    "url": "https://finnhub.io/api/news?id=dbc8c277643503cee94d9cd338441320278f35097cc41fc1e9cb35738f7f2635",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761553908,
      "headline": "Novartis to Acquire Avidity Biosciences for $72 per Share",
      "id": 137228524,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th",
      "url": "https://finnhub.io/api/news?id=dbc8c277643503cee94d9cd338441320278f35097cc41fc1e9cb35738f7f2635"
    }
  }
]